BEGIN:VCALENDAR VERSION:2.0 PRODID:-//The BioCalendar - ECPv6.15.20//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:The BioCalendar X-ORIGINAL-URL:https://thebiocalendar.com X-WR-CALDESC:Events for The BioCalendar REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/Los_Angeles BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20250309T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20251102T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20260308T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20261101T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20270314T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20271107T090000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/New_York BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20250309T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20251102T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20260308T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20261101T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20270314T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20271107T060000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260604T110000 DTEND;TZID=America/Los_Angeles:20260604T120000 DTSTAMP:20260430T025357 CREATED:20260417T125838Z LAST-MODIFIED:20260417T125838Z UID:10226-1780570800-1780574400@thebiocalendar.com SUMMARY:Supporting Efficient mAb Development with a Flexible Downstream Purification Toolkit DESCRIPTION:Bringing innovative antibody therapeutics to market quickly requires more than upstream efficiency. It demands adaptable and robust downstream purification strategies. \nAs novel mAb formats increase in complexity\, purification challenges grow. Achieving required purity and yield often extends beyond traditional 2–3 step platform processes\, requiring expanded chromatography options and optimized buffer systems. \nIn this webinar\, we will discuss: \n – Practical strategies for designing a flexible downstream purification toolkit\n – Approaches to buffer optimization for challenging antibody molecules\n – Ways to streamline process development while maintaining performance \nRegister to learn how a well-designed purification toolkit can help accelerate development timelines and improve process robustness. URL:https://thebiocalendar.com/event/supporting-efficient-mab-development-with-a-flexible-downstream-purification-toolkit/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/06-04-26-Thermo-LinkedIn-1280x720-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20260603T110000 DTEND;TZID=America/New_York:20260603T120000 DTSTAMP:20260430T025357 CREATED:20260428T162322Z LAST-MODIFIED:20260428T174809Z UID:10268-1780484400-1780488000@thebiocalendar.com SUMMARY:Hidden in Plain Sight: How Solid-State Science Solves Your Toughest API Challenges DESCRIPTION:This webinar series explores two powerful\, complementary disciplines that CDMOs leverage to tackle these challenges head-on. First\, we examine the solid-state domain\, exploring how targeted crystallization development can directly address purification\, filtration\, stability\, and processability challenges from lab scale through commercialization. Then\, we see how chromatographic modeling tools in combination with innovative techniques like “fraction mapping\,” can improve efficiency\, recovery\, and purity across various scales URL:https://thebiocalendar.com/event/hidden-in-plain-sight-how-solid-state-science-solves-your-toughest-api-challenges/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/06-03-26-MilliporeSigma-Reg-1920x250-PART-ONE.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20260603T100000 DTEND;TZID=America/New_York:20260603T110000 DTSTAMP:20260430T025357 CREATED:20260428T174731Z LAST-MODIFIED:20260428T174731Z UID:10272-1780480800-1780484400@thebiocalendar.com SUMMARY:2026 Manufacturing Trends Reshaping Life Sciences: AI\, Integration\, and Workforce Readiness DESCRIPTION:The webinar also highlights the growing role of AI within regulated manufacturing environments. Rather than treating AI as an add-on\, the session outlines how to embed it into validated frameworks to support predictive maintenance\, yield optimization\, and faster product release cycles. URL:https://thebiocalendar.com/event/2026-manufacturing-trends-reshaping-life-sciences-ai-integration-and-workforce-readiness-2/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/06-03-26-MilliporeSigma-Reg-1920x250-PART-ONE-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260603T083000 DTEND;TZID=America/Los_Angeles:20260603T150000 DTSTAMP:20260430T025357 CREATED:20260419T120546Z LAST-MODIFIED:20260419T120546Z UID:10231-1780475400-1780498800@thebiocalendar.com SUMMARY:Better Together: A Pharma & Biotech EHS Forum DESCRIPTION:Reimagine what’s possible—together.\nJoin BSI Consulting for an expert-led forum designed for pharma and biotech professionals who are shaping the next era of EHS. Connect with peers\, challenge assumptions\, and explore practical solutions to the industry’s most pressing risks and opportunities. \nThis event brings together leaders at the forefront of life sciences in EHS to learn\, debate\, and reimagine what’s possible. \nFeaturing speakers from:  \nAstraZeneca · Intellia Therapeutics · Leading multinational biotech organizations · BSI Consulting \nWhat you’ll experience\nDuring this one-day event\, you’ll be part of conversations that matter. \nKeynote spotlight: AI Large and Small  \nHear from an AI practitioner on the types of automation systems to support problem-solving\, and the opportunities and limitations of AI use. \nMulti-track roundtables with leading organizations  \nJoin guest speakers and BSI Consulting as they explore: \n\nBridging competency gaps across EHS teams.\nUnseen risks of waste misclassification in labs and R&D environments.\nAI governance\, compliance\, and date integrity in life sciences.\nBuilding biosafety systems that move beyond minimum compliance.\nSupply chain risk – details to be announced soon! \n\nInteractive discussions \nCollaborate in facilitated groups to identify shared industry challenges and co-create actionable solutions. \nYou’ll walk away with new relationships\, practical insights\, and a renewed sense of purpose in your work. \nView the full agenda! URL:https://thebiocalendar.com/event/better-together-a-pharma-biotech-ehs-forum/ LOCATION:Boston\, MA\, 02210\, United States CATEGORIES:Forum END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260602T163000 DTEND;TZID=America/Los_Angeles:20260602T190000 DTSTAMP:20260430T025357 CREATED:20260428T142837Z LAST-MODIFIED:20260428T142837Z UID:10260-1780417800-1780426800@thebiocalendar.com SUMMARY:BVS' Biotech Community Event at SOVA Science District\, San Diego DESCRIPTION:We are very excited to announce our outdoor Biotech Community Event at SOVA Science District. \nThis is a great opportunity to connect with industry leaders\, explore innovative products\, and mingle with fellow professionals in the biotech community. \nOur last events were a HUGE success with 300 high-quality people registering from over 100+ companies/institutes & we will once again be inviting the entire So CA Life Science Community to attend. \n✨ What to Expect: \n Vendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\n Networking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\n Delicious Tacos & Beer: Enjoy delicious Tacos as you network and explore the vendor exhibits. \nAdmission Details: \n FREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, non-sales/bus dev positions\,etc.) from life science companies and research institutes.\n $200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nPlease feel free to invite others in the community that could benefit from attending. \nWe look forward to seeing you there! URL:https://thebiocalendar.com/event/bvs-biotech-community-event-at-sova-science-district-san-diego-10/ ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/04/BVS-Biotech-Event-Flyer-06-2-26.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260602T080000 DTEND;TZID=America/Los_Angeles:20260602T123000 DTSTAMP:20260430T025357 CREATED:20260327T140751Z LAST-MODIFIED:20260327T140751Z UID:10107-1780387200-1780403400@thebiocalendar.com SUMMARY:Boston Life Sciences Conference DESCRIPTION:What You’ll Learn: \n\nHow does life sciences continue to be Boston’s and Cambridge’s economic engine amid a softening market?\nWith total VC investment at $6.85B across 197 rounds in 2025\, is capital concentrating into fewer winners\, and how is that changing tenant decision making?\nWhere are AI enabled life sciences users\, automation heavy labs\, and data driven R and D teams showing up in Cambridge and Greater Boston?\nHow have significant projects in the area played a role in shaping the growth and development of the biotechnology and life science sectors?\nWhich incentives\, workforce programs\, and state tools are still available to support expansions and manufacturing growth in Massachusetts?\nWith Greater Boston lab vacancy at 28.0% in Q4 2025\, what is the realistic timeline and mechanism for absorption?\nWhat types of tenants are active in the market right now for space\, and what kind of space are they leasing up? \nWhat product is winning leasing right now: incubator\, flex lab\, mid scale growth space\, or larger HQ and R&D?\n\nHow you’ll do more business: \nConnect with industry leaders to explore emerging leasing dynamics and market trends\, and gain valuable insights on the current state of the sector. Discover cutting-edge innovations in workplace flexibility and design. Explore topics like sustainable facility design\, power solutions and access considerations and other crucial aspects that can enhance your business strategy.  \nWho attends: \nInvestors\, owners\, developers\, tenants\, end users\, brokers\, lawyers\, designers\, contractors\, architects\, property managers and more! \nWhy should you attend: \nBisnow events bring together the biggest power players in the industry to identify opportunities\, build your network\, and expand your business. With the largest audience of commercial real estate professionals in the world\, no one knows how to help your business more than us. URL:https://thebiocalendar.com/event/boston-life-sciences-conference-2/ LOCATION:Boston\, MA\, 02210\, United States CATEGORIES:Summit END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260602 DTEND;VALUE=DATE:20260605 DTSTAMP:20260430T025357 CREATED:20260415T152522Z LAST-MODIFIED:20260415T152610Z UID:10200-1780358400-1780617599@thebiocalendar.com SUMMARY:Global Healthcare Conference in New York DESCRIPTION:By invitation only.  You must be pre-registered by your Jefferies representative in order to attend. \nThe Jefferies Global Healthcare Conference in New York will take place on Tuesday\, June 2 – Thursday June 4\, 2026. This year’s conference will focus on life sciences companies in the biotechnology\, life sciences tools and services\, medical technology\, and pharmaceutical sectors. \nWe will dedicate Tuesday\, June 2 to private companies only. The format will consist of 1x1s and small group meetings between select private companies and investors. There will be no presentations.  On Wednesday\, June 3 & Thursday\, June 4\, we will host over 300 public companies for two full days of presentations\, fireside chats\, 1x1s and small group meetings. \nWe look forward to organizing another exciting conference\, as we bring together over 3\,000 leading executives\, institutional investors\, private equity investors & VCs to address near- and long-term investment opportunities and discuss the current trends driving healthcare in the U.S. and internationally. URL:https://thebiocalendar.com/event/global-healthcare-conference-in-new-york/ LOCATION:New York\, New York\, NY\, United States CATEGORIES:Investor ATTACH;FMTTYPE=image/webp:https://thebiocalendar.com/wp-content/uploads/2026/04/Global-HC-Conf-New-York-2026-Web-Tile-1200x490px-300dpi.webp END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260529T110000 DTEND;TZID=America/Los_Angeles:20260529T120000 DTSTAMP:20260430T025357 CREATED:20260429T155001Z LAST-MODIFIED:20260429T155001Z UID:10304-1780052400-1780056000@thebiocalendar.com SUMMARY:CAR-T Strategy in 2026: Scaling Autologous\, Advancing Allogeneic DESCRIPTION:Join this thought leadership panel exploring how the CAR-T landscape continues to evolve as clinical and commercial experience grows. As autologous therapies expand into additional settings and allogeneic approaches continue to be studied\, organizations are reassessing where to focus research\, development\, and operational efforts. \nThis discussion brings together perspectives from across the cell therapy ecosystem to examine key scientific\, operational\, and market considerations shaping CAR-T development in 2026 and beyond. \nWhat you will learn:\n ~ Differences in the current use and development of autologous and allogeneic CAR-T therapies\n ~ Factors influencing manufacturing\, supply chain\, and clinical approaches\n ~ Regulatory\, commercial\, and operational considerations\n ~ Areas of ongoing development and uncertainty \nKey topics include:\n ~ Modality strategy: roles of autologous vs allogeneic approaches\n ~ Manufacturing: scalability\, consistency\, and process control\n ~ Clinical development: expansion and durability considerations\n ~ Access: reimbursement and site-of-care factors\n ~ Regulatory & CMC: expectations and comparability\n ~ Supply chain: patient-specific vs off-the-shelf models\n ~ Collaboration: cross-sector partnership approaches \nThis panel provides perspectives on how organizations are approaching CAR-T strategy\, including near-term priorities and longer-term considerations. URL:https://thebiocalendar.com/event/car-t-strategy-in-2026-scaling-autologous-advancing-allogeneic/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-29-26-Thermo-LinkedIn-1280x720-1.png END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260528 DTEND;VALUE=DATE:20260603 DTSTAMP:20260430T025357 CREATED:20260311T084731Z LAST-MODIFIED:20260311T084731Z UID:10011-1779926400-1780444799@thebiocalendar.com SUMMARY:BIO Partnering for Oncology DESCRIPTION:Connect with innovators\, investors\, and companies advancing cancer breakthroughs\, in person or virtually\, during Chicago’s biggest oncology event through the BIO Partnering™ system. URL:https://thebiocalendar.com/event/bio-partnering-for-oncology/ LOCATION:Chicago\, Chicago\, IL\, United States END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260527T160000 DTEND;TZID=America/Los_Angeles:20260527T183000 DTSTAMP:20260430T025357 CREATED:20260428T143147Z LAST-MODIFIED:20260428T143147Z UID:10264-1779897600-1779906600@thebiocalendar.com SUMMARY:BVS and BioMed Realty's Biotech Community Event in SSF DESCRIPTION:Join Us for the BVS and BioMed Realty Biotech Community Event! \nMark your calendars for a great opportunity to connect with industry leaders\, explore innovative products\, and mingle with fellow professionals in the biotech community. \nThe vendor fair is held at The Forum\, in the same building as Amgen and next to Genentech\, right in the heart of the large pharma/biotechs in South San Francisco. \n✨ What to Expect: \n Vendor Exhibit: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\n Networking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\n Appetizers & Drinks: Enjoy delicious refreshments as you network and explore the vendor exhibits. \nWe welcome the entire Bay Area Biotech Community to join us for this exciting event! This is a wonderful chance for everyone to come together\, share insights\, and celebrate the vibrant biotech landscape in our region. \nAdmission Details: \n FREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, non-sales/bus dev positions etc.) from life science companies and research institutes. \n $200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nPlease feel free to invite others in the community that could benefit from attending. \nWe look forward to seeing you there! URL:https://thebiocalendar.com/event/bvs-and-biomed-realtys-biotech-community-event-in-ssf-7/ ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/04/Biomed-Event-Flyer-05-27-26-Flyer.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260527T100000 DTEND;TZID=America/Los_Angeles:20260527T110000 DTSTAMP:20260430T025357 CREATED:20260421T144957Z LAST-MODIFIED:20260421T144957Z UID:10237-1779876000-1779879600@thebiocalendar.com SUMMARY:Simplifying ADC Analysis: Real-Time DAR and Concentration Measurement Without Dilution DESCRIPTION:Antibody-drug conjugates (ADCs) present unique analytical challenges\, particularly in maintaining consistent drug-to-antibody ratio (DAR)\, minimizing variability\, and reducing reliance on time-intensive off-line methods. These challenges are further compounded by the need to limit handling of highly potent payloads while maintaining process control. \nThis webinar explores how variable pathlength spectroscopy enables rapid\, accurate at-line and in-line measurement of both concentration and DAR throughout ADC development and manufacturing. \nThrough real-world case studies\, you’ll see how replacing traditional UV-Vis workflows with slope-based analysis eliminates dilution steps\, reduces error\, and accelerates decision-making. We will also demonstrate how integrating real-time in-line data supports improved process understanding\, tighter control during TFF\, and more efficient scale-up. \nJoin us to learn how applying Process Analytical Technology (PAT) principles can simplify ADC workflows\, reduce risk\, and drive more consistent process outcomes. \nKey Learning Objectives:\n How variable pathlength spectroscopy (VPT) works to measure concentration and DAR without dilution\n How to apply at-line and in-line VPT to generate real-time data for improved ADC process understanding\n How to reduce analytical variability\, operator handling\, and process risk compared to traditional UV-Vis methods URL:https://thebiocalendar.com/event/simplifying-adc-analysis-real-time-dar-and-concentration-measurement-without-dilution/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-27-26-Repligen-Reg-1920x250-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260521T130000 DTEND;TZID=America/Los_Angeles:20260521T140000 DTSTAMP:20260430T025357 CREATED:20260422T124701Z LAST-MODIFIED:20260422T124701Z UID:10241-1779368400-1779372000@thebiocalendar.com SUMMARY:Advancing Therapeutic Discovery With Reproducible High Throughput Electroporation DESCRIPTION:As demand for advanced therapies continues to surge\, the biopharma industry is under pressure to innovate faster in high-risk areas like drug discovery and cell therapy. These fields face persistent challenges\, such as high costs\, long development timelines\, and complex regulatory landscapes. To that end\, MaxCyte has introduced a new high-throughput electroporation platform that streamlines genetic material delivery with speed\, precision\, and scalability. \nThis new platform can process up to 96 samples in under three minutes\, allowing independent optimization and minimal waste. It’s designed to support seamless scalability from small-scale discovery to large-volume\, GMP-compliant manufacturing\, integrating with the MaxCyte ExPERT platform. \nDuring this webinar\, we’ll explore how the new software enables fine-tuned energy delivery across diverse cell types\, including hard-to-transfect immune cells. We’ll also walk through real-world applications\, such as optimizing non-viral CAR-T engineering using CRISPR-Cas9\, demonstrating high-throughput efficiency\, with consistent reproducibility. \nKey Learning Objectives:\n– Understand how high-throughput electroporation can address key barriers\, such as accelerating timelines and high cost\n– Explore the capabilities of MaxCyte’s new electroporation platform\, including rapid sample processing and customizable energy delivery\n– Gain practical insights into high-throughput screening workflows\, such as CAR-T cell engineering via CRISPR knock-in URL:https://thebiocalendar.com/event/advancing-therapeutic-discovery-with-reproducible-high-throughput-electroporation/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-21-26-MaxCyte-eBlast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260521T110000 DTEND;TZID=America/Los_Angeles:20260521T120000 DTSTAMP:20260430T025357 CREATED:20260422T165752Z LAST-MODIFIED:20260422T165752Z UID:10249-1779361200-1779364800@thebiocalendar.com SUMMARY:The Stakeholder Impact of Centralized Trial Services DESCRIPTION:This sponsor-led webinar will explore the real-world impact of using a centralized trial services platform through firsthand experiences from both Cogent and Helus Pharma. Discover how working with a single partner to manage patient logistics\, site payments\, and financial coordination influenced day-to-day trial operations\, communication across stakeholders\, and the overall experience for sites and participants. By hearing directly from sponsors across different trial types\, attendees will gain practical insight into how a centralized approach can support more efficient and coordinated study execution. \nThe session will begin with a brief look at the growing complexity of modern clinical trials\, particularly those that are hybrid\, global\, and reliant on multiple vendors. From there\, Cogent and Helus Pharma will walk through their own trial contexts\, the operational challenges they encountered\, and why they ultimately chose a centralized approach. The webinar will conclude with a discussion of the common themes that emerged across both experiences\, along with high-level implementation insights from Block Clinical. \nKey Learning Objectives:\n– How centralizing patient logistics\, site payments\, and financial coordination can reduce administrative burden and improve communication across sponsors\, sites\, and patients\n– Real-world perspectives from two independent sponsors on how centralized services impacted site coordination\, patient experience\, and sponsor-level oversight\n– Practical considerations for implementing a centralized approach\, including common challenges and how sponsors address them in active trials URL:https://thebiocalendar.com/event/the-stakeholder-impact-of-centralized-trial-services/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-21-26-Block-eBlast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260520T160000 DTEND;TZID=America/Los_Angeles:20260520T183000 DTSTAMP:20260430T025357 CREATED:20260415T163842Z LAST-MODIFIED:20260415T163842Z UID:10202-1779292800-1779301800@thebiocalendar.com SUMMARY:BVS' Biotech Community Event at Biovista\, San Diego DESCRIPTION:We are very excited to announce our outdoor Biotech Community Event at the Biovista Life Science Campus. \nMark your calendars for a great opportunity to connect with industry leaders\, explore innovative products\, and mingle with fellow professionals in the biotech community. \n✨ What to Expect: \n Vendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\n Networking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\n Delicious Appetizers by California English & Drinks: Enjoy delicious appetizers as you network and explore the vendor exhibits. \nWe are inviting all the tenants and all local life science researchers and entrepreneurs in the surrounding area to attend. \nAdmission Details:\nFREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, non-sales/bus dev positions etc.) from life science companies and research institutes.\n$200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nPlease feel free to invite others in the community that could benefit from attending. \nWe look forward to seeing you there! URL:https://thebiocalendar.com/event/bvs-biotech-community-event-at-biovista-san-diego-3/ ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/04/BVS-Biotech-Event-Flyer-05-20-26.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260520T130000 DTEND;TZID=America/Los_Angeles:20260520T140000 DTSTAMP:20260430T025357 CREATED:20260429T125734Z LAST-MODIFIED:20260429T125734Z UID:10300-1779282000-1779285600@thebiocalendar.com SUMMARY:Outsourced Pharma Capabilities Update May 2026: Large Molecule DESCRIPTION:Watch Leading CDMOs share their current capabilities\, facility locations\, and timelines – to help you identify options for your development and manufacturing needs. \nDive into the biopharmaceutical realm\, where the synthesis of biologically derived APIs encompasses cell line development\, fermentation\, and sophisticated purification techniques. The event will feature insights into process optimization and scale-up\, which are crucial for meeting production demands without compromising quality. Discover the meticulous quality control practices that underpin the production of biopharmaceuticals\, laying the groundwork for novel biologic therapies. \nWhat can you expect? – Short\, digital presentations to give you an inside look at the current capabilities of industry suppliers. You will have the opportunity to submit questions of each CDMO to better understand if they can meet your needs – all from the convenience of your computer! URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-may-2026-large-molecule/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/Biocal-19.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260520T130000 DTEND;TZID=America/Los_Angeles:20260520T140000 DTSTAMP:20260430T025357 CREATED:20260421T103753Z LAST-MODIFIED:20260421T103753Z UID:10233-1779282000-1779285600@thebiocalendar.com SUMMARY:Cleanroom ISO Classification: The Framework for Containment in a Cleanroom DESCRIPTION:Cleanroom ISO classification is a foundational decision that directly impacts facility design\, GMP manufacturing operations\, and regulatory outcomes in biotech and pharmaceutical environments. This is especially critical in cell and gene therapy\, viral vector\, API\, mRNA\, and sterile ATMP manufacturing\, where product protection\, biohazard containment\, and operator safety must be carefully balanced. \nIn this webinar\, we’ll explore how ISO classification strategy shapes key aspects of cleanroom design\, including process layout\, HVAC system design\, air change rates\, pressurization schemes\, and airlock sequencing in Biosafety Level and OEB-driven environments. \nAttendees will learn why early alignment between process operations\, containment strategy\, and regulatory expectations is essential when working with biohazardous materials\, high-potency compounds\, and patient-specific therapies. Without this alignment\, organizations risk costly redesigns\, operational inefficiencies\, and compliance challenges. \nWe’ll also examine how misaligned classification decisions can limit manufacturing flexibility\, increase operator exposure risk\, and weaken containment strategies. \nDrawing on real-world project experience across viral vector and cell processing facilities\, this session will demonstrate how integrating ISO classification into early design phases supports effective containment\, cross-contamination control\, and inspection readiness. The webinar will emphasize practical approaches to aligning cleanroom infrastructure with process needs to help you build safe\, compliant\, and scalable ATMP manufacturing operations that meet both current and future goals. \nKey Learning Objectives:\n– Understand how ISO classification drives cleanroom containment\, HVAC system approach\, pressurization strategies\, airlock scheme\, and GMP manufacturing quality\n – Identify compliance\, cross-contamination and operational risks caused by misaligned ISO classification strategies in ATMP manufacturing cleanrooms\n – Recognize the relationship between process operations\, contamination risk\, and ISO classification selection through early planning to support inspection readiness URL:https://thebiocalendar.com/event/cleanroom-iso-classification-the-framework-for-containment-in-a-cleanroom/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-20-26-AES-LinkedIn-1280x720-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260520T110000 DTEND;TZID=America/Los_Angeles:20260520T120000 DTSTAMP:20260430T025357 CREATED:20260429T125556Z LAST-MODIFIED:20260429T125556Z UID:10296-1779274800-1779278400@thebiocalendar.com SUMMARY:Outsourced Pharma Capabilities Update May 2026: Combination Products & Drug Delivery DESCRIPTION:The move toward self-administered\, home-based treatments has made drug–device combination products a strategic priority. Success now requires tight integration across formulation\, device design\, testing\, human factors\, and regulatory strategy—not separate workflows. \nThis session outlines the key decisions and capabilities for successful programs\, including choosing platform vs. custom devices\, ensuring formulation–device compatibility\, and meeting testing standards. It also covers regulatory expectations\, human factors validation\, and scaling manufacturing for autoinjectors and wearables—plus how early planning and emerging digital strategies can reduce risk and accelerate development. URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-may-2026-combination-products-drug-delivery/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/Biocal-18.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260519T130000 DTEND;TZID=America/Los_Angeles:20260519T140000 DTSTAMP:20260430T025357 CREATED:20260429T125254Z LAST-MODIFIED:20260429T125254Z UID:10292-1779195600-1779199200@thebiocalendar.com SUMMARY:Outsourced Pharma Capabilities Update May 2026: Highly Potent Drug Development & Manufacturing DESCRIPTION:This event brings together pharmaceutical and biotech professionals\, CDMOs\, and technology providers to discuss the development and manufacturing of highly potent active pharmaceutical ingredients (HPAPIs). This event shares presentations focused on key topics such as containment technologies\, process scale-up\, regulatory compliance\, and occupational safety in HPAPI manufacturing. The event also serves as a networking platform where CDMOs showcase their capabilities—such as specialized facilities\, containment systems\, and expertise in handling highly toxic compounds—allowing pharma and biopharma companies to evaluate potential outsourcing and development partners. \nPurpose for attendees:\n– Enable CDMOs to present their technical capabilities and facilities for handling potent compounds\n– Facilitate partnership discussions and outsourcing opportunities in drug development and manufacturing URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-may-2026-highly-potent-drug-development-manufacturing/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/Biocal-17.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260519T110000 DTEND;TZID=America/Los_Angeles:20260519T120000 DTSTAMP:20260430T025357 CREATED:20260429T125014Z LAST-MODIFIED:20260429T125014Z UID:10288-1779188400-1779192000@thebiocalendar.com SUMMARY:Outsourced Pharma Capabilities Update May 2026: Mammalian Cell Culture DESCRIPTION:This online event brings together pharmaceutical and biotechnology companies with contract development and manufacturing organizations (CDMOs) specializing in mammalian cell culture–based biologics production. Through a series of concise presentations\, participating CDMOs showcase their capabilities across the biologics development lifecycle\, including cell line development\, upstream and downstream process development\, scale-up\, and GMP manufacturing. \nThe event is designed to help drug developers evaluate potential outsourcing partners by highlighting available capacity\, technical platforms\, facility infrastructure\, and expertise in producing complex biologics such as monoclonal antibodies and recombinant proteins. Attendees gain practical insights into manufacturing strategies\, timelines\, and partnership models while having the opportunity to engage directly with CDMO experts to determine the best fit for their development and commercialization needs. URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-may-2026-mammalian-cell-culture/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/Biocal-16.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260519T110000 DTEND;TZID=America/Los_Angeles:20260519T120000 DTSTAMP:20260430T025357 CREATED:20260422T125020Z LAST-MODIFIED:20260422T125020Z UID:10245-1779188400-1779192000@thebiocalendar.com SUMMARY:From Protocol to Patient Risk: How to Build Safer\, Faster Trials by Integrating Clinical Operations and Pharmacovigilance Early DESCRIPTION:Clinical execution and pharmacovigilance are often managed in parallel rather than in partnership. For sponsors\, that disconnect can create avoidable delays\, inconsistent safety decision-making\, protocol amendments\, and added pressure on sites and study teams. In early-phase and complex trials\, where risk profiles are still emerging\, these gaps can have a direct impact on both patient safety and development timelines. \nJoin experts from Ergomed Clinical Research and PrimeVigilance for a practical discussion on how earlier integration across clinical operations\, medical monitoring\, and pharmacovigilance can strengthen study oversight from the outset. This webinar will examine where silos tend to emerge\, how integrated planning can reduce downstream issues\, and what sponsors can do to build a more connected model across protocol strategy\, trial conduct\, individual case safety report handling\, and signal and risk management. \nAttendees will gain practical insight into how a more aligned clinical and safety strategy can support better benefit-risk decisions\, reduce operational risk\, and help keep complex studies on track. \nKey Takeaways:\n– Why separating clinical operations and safety oversight creates avoidable risk in clinical development\n– Where silos most often create issues\, including delayed decisions\, protocol amendments\, inconsistent safety data handling incl. signal and risk management\, and added site burden\n– What integrated planning and execution looks like in practice across study design\, medical monitoring\, pharmacovigilance\, and trial conduct\n– How earlier collaboration can support stronger decision-making\, operational readiness\, and timeline protection\n– Practical ways to reduce downstream risk while improving both patient safety and study efficiency URL:https://thebiocalendar.com/event/from-protocol-to-patient-risk-how-to-build-safer-faster-trials-by-integrating-clinical-operations-and-pharmacovigilance-early/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-19-26-Ergomed-eblast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260519 DTEND;VALUE=DATE:20260522 DTSTAMP:20260430T025357 CREATED:20260227T112059Z LAST-MODIFIED:20260228T120528Z UID:9981-1779148800-1779407999@thebiocalendar.com SUMMARY:Health & Business Growth Summit Zagreb DESCRIPTION:Health & Business Growth Summit Zagreb 2026 is an international event that brings together experts\, entrepreneurs\, and innovators from the healthcare and business sectors. Over the course of three days\, the summit features a combination of inspiring keynote talks\, panel discussions\, an exhibition area\, and networking opportunities\, all focused on development\, growth\, and global expansion of healthtech and medtech solutions. The goal of the summit is to connect leading professionals\, investors\, hospitals\, insurers\, and entrepreneurs\, and to encourage the creation of new partnerships\, funding opportunities\, and business advancement. \nThe Health & Business Growth Summit is the first event of its kind in Croatia\, designed to position Zagreb as a CEE gateway\, bridging regional innovators and advanced European healthcare ecosystems. \nThe summit is organized by Proqlea\, a Zagreb-based pharmaceutical company specialized in CRO services and regulatory consulting. Our goal is to create an international platform connecting healthcare entrepreneurs\, innovators\, MedTech startups\, investors\, and support institutions through: \n– Inspirational keynote lectures\n– Dynamic panel discussions\n– Exhibition space\n– Exclusive VIP networking\n– Pitch sessions organized by NetHub \nWe place special emphasis on young entrepreneurs\, startups\, and SMEs\, providing them with key information and contacts for growth and entry into foreign markets\, as well as facilitating the entry of international entrepreneurs into Croatia. URL:https://thebiocalendar.com/event/health-business-growth-summit-zagreb/ LOCATION:Zagreb\, Zagreb\, Zagreb\, 10000\, Croatia (Local Name: Hrvatska) CATEGORIES:Summit END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260519 DTEND;VALUE=DATE:20260522 DTSTAMP:20260430T025357 CREATED:20260420T150251Z LAST-MODIFIED:20260420T150251Z UID:10232-1779148800-1779407999@thebiocalendar.com SUMMARY:LEAP HR: Life Sciences West DESCRIPTION:Returning for its 8th year\, LEAP HR: Life Sciences West reunites 100+ senior HR leaders from scaling and stabilizing biotech organizations to uncover how to navigate volatility\, unlock peer-led insights\, and deliver tangible business impact. \nAcross three days of high-impact content\, you’ll gain actionable takeaways through case studies\, benchmarking sessions\, structured networking\, roundtable discussions\, and speed learning. From navigating immigration shifts and political change to building lean HR functions and retaining talent in a competitive market\, this is the only forum dedicated to tackling the unique people challenges facing West Coast life sciences organizations. \nJoin us this May to connect with forward–thinking HR leaders and discover how to lead with clarity\, creativity\, and confidence in a rapidly evolving operating environment. URL:https://thebiocalendar.com/event/leap-hr-life-sciences-west-2/ LOCATION:San Diego\, San Diego\, CA\, United States CATEGORIES:Forum,Summit END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260519 DTEND;VALUE=DATE:20260522 DTSTAMP:20260430T025357 CREATED:20251206T101304Z LAST-MODIFIED:20251206T101316Z UID:9624-1779148800-1779407999@thebiocalendar.com SUMMARY:Bio-IT Conference & Expo DESCRIPTION:The Bio-IT World Conference & Expo is the premier global event showcasing technologies and analytic approaches that solve problems\, accelerate science\, and drive the future of precision medicine. Now in its 25th year\, the event convenes more than 2\,900 leaders from biopharma\, clinical research\, healthcare\, informatics\, and technology to exchange ideas\, showcase solutions\, and spark collaborations that push the boundaries of biomedical research\, drug discovery\, and patient outcomes. Spanning 200+ sessions—including plenary keynotes\, symposia\, technical workshops\, and hands-on demonstrations—Bio-IT World offers unmatched opportunities to explore the tools\, platforms\, and strategies redefining R&D and clinical care. From AI\, generative AI\, and machine learning to multimodal and real-world data strategies\, FAIR/Open Source practices\, pilot programs\, new product launches\, and biotech investment trends\, attendees engage in transformative conversations that translate innovation into measurable value. \nAt its core\, Bio-IT World is more than a conference—it is a community driving discovery\, accelerating science\, and shaping the conversations that define the next era of precision medicine. URL:https://thebiocalendar.com/event/bio-it-conference-expo-2/ LOCATION:Boston\, MA\, 02210\, United States CATEGORIES:Expo END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260515T200000 DTEND;TZID=America/Los_Angeles:20260515T233000 DTSTAMP:20260430T025357 CREATED:20260424T160017Z LAST-MODIFIED:20260424T160017Z UID:10253-1778875200-1778887800@thebiocalendar.com SUMMARY:Concert for Cures: P!NK DESCRIPTION:This year\, Curebound is proud to welcome one of the world’s most celebrated and beloved artists: P!NK \nTickets on sale now!  \nSince bursting onto the scene in 2000\, P!NK has built a career defined by fearless honesty\, unforgettable live shows\, and a refusal to fit a mold. Across nine studio albums and a greatest hits collection\, she’s sold over 60 million albums worldwide\, earned 15 Top 10 hits on the Billboard Hot 100 (including four #1s)\, and packed-out arenas and stadiums across the globe with her high-energy\, high-flying performances. \nHer work has been recognized with three Grammy Awards (and 21 nominations) and she was named Billboard Music Awards’ Icon in 2021 and iHeartRadio’s Icon in 2023. A trailblazer and passionate advocate for the causes she holds dear\, P!NK continues to evolve — staying true to herself and inspiring millions to do the same. \nThe event is recognized for bringing together community energy to fund research that changes how cancer is detected\, treated\, and survived. Tickets and information for the 2026 event are available at Curebound.org. URL:https://thebiocalendar.com/event/concert-for-cures-pnk/ LOCATION:San Diego\, San Diego\, CA\, United States CATEGORIES:Fundraiser,Social END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260514T110000 DTEND;TZID=America/Los_Angeles:20260514T120000 DTSTAMP:20260430T025357 CREATED:20260429T123929Z LAST-MODIFIED:20260429T123929Z UID:10284-1778756400-1778760000@thebiocalendar.com SUMMARY:Strategic Early Material Generation for Accelerated Process Development DESCRIPTION:Rapid access to early-stage material is critical for biologics development\, especially as molecular complexity increases and timelines expand. Generating scalable\, high-quality material early helps streamline developability assessments and process development. \nIn this webinar\, Samsung Biologics presents its strategy for early material generation\, integrating it with cell line development (CLD)\, early optimization\, and stable expression platforms. This approach delivers consistent\, production-relevant material—nearly equivalent to single-clone sources—while reducing variability\, time\, and complexity. \nLearn how this streamlined workflow accelerates development from sequence to material\, supports downstream activities\, and improves efficiency. Case studies will highlight scalable production from flask to bioreactor and the impact of early decisions on timelines and costs. \nKey benefits:\n– Faster\, more efficient early-stage biologics development\n– Improved scalability through alignment with CLD\n– Reliable material supply for process and formulation studies URL:https://thebiocalendar.com/event/strategic-early-material-generation-for-accelerated-process-development-2/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-14-26-Samsung-eblast-700x200-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260514T110000 DTEND;TZID=America/Los_Angeles:20260514T120000 DTSTAMP:20260430T025357 CREATED:20260429T123708Z LAST-MODIFIED:20260429T123708Z UID:10280-1778756400-1778760000@thebiocalendar.com SUMMARY:Understanding the Regulatory Landscape for Ophthalmic Drug Products: Contamination Control Strategies\, USP \, and Purpose-Built Solutions DESCRIPTION:Ophthalmic drugs face strict regulations\, including USP limits on particulate matter and updated EU GMP Annex 1 requirements for comprehensive Contamination Control Strategies (CCS). These standards emphasize minimizing contamination across packaging\, sterilization\, and system controls. \nThis webinar explores how these regulations impact real-world development challenges and how purpose-built packaging—featuring low particulates\, silicone-free designs\, and advanced barrier technologies—can support compliance\, improve dose accuracy\, and reduce risk. \nYou’ll learn:\n– The role of CCS in reducing contamination risks\n– Key regulatory requirements\, including USP\n– Common challenges like particulates\, silicone oil\, and endotoxins\n– Packaging solutions for safer ophthalmic drug delivery \nKey takeaways:\n– Build an effective CCS\n– Understand ophthalmic vs. injectable requirements\n– Interpret USP limits\n– Evaluate solutions for compliant drug delivery URL:https://thebiocalendar.com/event/understanding-the-regulatory-landscape-for-ophthalmic-drug-products-contamination-control-strategies-usp-and-purpose-built-solutions-2/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-14-26-West-eBlast-700x200-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260514T110000 DTEND;TZID=America/Los_Angeles:20260514T120000 DTSTAMP:20260430T025357 CREATED:20260416T191238Z LAST-MODIFIED:20260416T191238Z UID:10218-1778756400-1778760000@thebiocalendar.com SUMMARY:Understanding the Regulatory Landscape for Ophthalmic Drug Products: Contamination Control Strategies\, USP \, and Purpose-Built Solutions DESCRIPTION:Navigate the increasingly complex regulatory landscape for ophthalmic drug products by understanding key standards such as USP and EU GMP Annex 1\, and how they drive the need for robust Contamination Control Strategies (CCS). This webinar explores how developers can address real-world manufacturing and compliance challenges while improving product quality and patient safety through purpose-built packaging and delivery solutions. \nKey takeaways:\n– Develop an effective Contamination Control Strategy (CCS)\n– Differentiate the regulatory requirements for ophthalmic drug products compared with standard injectables\n– Interpret USP  particle limits and their implications for intraocular drug administration\n– Evaluate available solutions that support ophthalmic drug delivery URL:https://thebiocalendar.com/event/understanding-the-regulatory-landscape-for-ophthalmic-drug-products-contamination-control-strategies-usp-and-purpose-built-solutions/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-14-26-West-eBlast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260514T110000 DTEND;TZID=America/Los_Angeles:20260514T120000 DTSTAMP:20260430T025357 CREATED:20260416T190955Z LAST-MODIFIED:20260416T190955Z UID:10214-1778756400-1778760000@thebiocalendar.com SUMMARY:Strategic Early Material Generation for Accelerated Process Development DESCRIPTION:Accelerate biologics development by enabling rapid access to scalable\, production-relevant early-stage material that supports developability assessment and process optimization. This webinar highlights Samsung Biologics’ integrated approach\, aligning material generation with cell line development\, incorporating early optimization\, and leveraging stable expression platforms to deliver consistent\, high-quality material with reduced variability. Learn how this streamlined strategy shortens timelines\, simplifies processes\, and improves resource efficiency\, supported by case studies demonstrating successful scale-up from flask to bioreactor. \nKey Takeaways:\n– The role of early material generation in enabling efficient biologics development and early developability assessment\n– How aligning material generation with cell line development supports both speed and scalability from early stages\n– How scalable\, production-relevant material supports process development activities\, including formulation studies and other material-intensive applications\, while improving overall time and resource efficiency URL:https://thebiocalendar.com/event/strategic-early-material-generation-for-accelerated-process-development/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-14-26-Samsung-eblast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260514T110000 DTEND;TZID=America/Los_Angeles:20260514T120000 DTSTAMP:20260430T025357 CREATED:20260409T125450Z LAST-MODIFIED:20260409T125450Z UID:10176-1778756400-1778760000@thebiocalendar.com SUMMARY:AI Meets Informed Consent: Opportunity\, Risk\, and What IRBs Need to See DESCRIPTION:The informed consent process is an ongoing dialogue that helps participants decide\, with full understanding\, whether to take part in a clinical trial. As generative AI begins to influence how consent documents are created\, translated\, and delivered\, this process is becoming more complex. \nJoin experts in IRB oversight\, research ethics\, and health literacy to explore the opportunities and challenges of AI-assisted informed consent. This session will cover ethical foundations\, emerging use cases for generative AI\, and what sponsors and CROs need to communicate to IRBs when using these tools. \nDesigned for clinical operations leaders across biopharma\, medtech\, and CROs\, this discussion will provide a practical framework for evaluating AI-driven consent approaches while keeping patient understanding and protection at the center. URL:https://thebiocalendar.com/event/ai-meets-informed-consent-opportunity-risk-and-what-irbs-need-to-see/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-14-26-Brany-eBlast-700x200-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260512T130000 DTEND;TZID=America/Los_Angeles:20260512T140000 DTSTAMP:20260430T025357 CREATED:20260413T161457Z LAST-MODIFIED:20260413T161458Z UID:10190-1778590800-1778594400@thebiocalendar.com SUMMARY:Don’t Sacrifice Compliance: Strategies for Audit-Ready System Integrations DESCRIPTION:Discover how modern integration strategies are enabling companies to bridge critical systems\, streamline data flow\, and maintain regulatory confidence that supports innovation and compliance\, so your systems evolve as fast as your business. URL:https://thebiocalendar.com/event/dont-sacrifice-compliance-strategies-for-audit-ready-system-integrations/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-12-26-Blue-Mountain-Reg-1920x250-rev.png END:VEVENT END:VCALENDAR